Grail, Inc. · NASDAQ:GRAL
Grail — Technical Presentation (November 2021)
14 slides from Grail's technical presentation, Nov 22, 2021
Slide 1: Conflict of Interest Statement
Conflict of Interest Statement ● This study was funded by GRAIL, LLC, a subsidiary of Illumina, Inc. CONFIDENTIAL & PROPRIETARY 1
Slide 2: Patient Preferences for Attributes of a Multi-cancer Early Detection Test: A Discrete Choice Experiment
Patient Preferences for Attr ibutes of a Multi-cancer Ear ly Detection Test: A Discr ete Choice Exper iment (DCE) Quantitative Pilot Study Heather Gelhorn1, Melissa Ross1, Anuraag R. Kansal2, Eric Fung2, Michael Seiden3, Karen C. Chung2 1Evidera, Bethesda, MD, USA; 2GRAIL, Menlo Park, CA, USA, 3McKe
Slide 3: Background
Background ● Early cancer detection and intervention can significantly improve patient outcomes and reduce mortality rates. ○ However, the number of cancers for which recommended screening procedures exist is limited (e.g., breast, lung, colorectal, and cervical). ● Emerging blood-based multi-cancer
Slide 4: Study Objective
Study Objective ● This study aimed to quantify preferences for attributes of blood-based MCED tests among the US general population aged 50 to 80 years. ● The results presented here are those from a quantitative pilot study that was conducted to test a discrete choice experiment (DCE) survey prior t
Slide 5: Methods
Methods Study Population Cr oss-Sectional Quantitative Pilot Web-Sur vey • US adults aged 50 to 80 years recruited This survey consisted of the following sections: via online panels 1. Introduction to the attributes and levels included in the DCE • Not currently receiving treatment for cancer • 3-mi
Slide 6: Example Choice Task
Example Choice Task Not an attribute, but added for clarity Always shown to participants in this order Either the first or last Opt out attribute shown (randomized) CONFIDENTIAL & PROPRIETARY 6
Slide 7: Statistical Analysis
Statistical Analysis ● Descriptive statistics were used to characterize the sample based on sociodemographic, clinical characteristics, and validity measures. ● DCE data were analyzed using an error-component multinomial logit (EC- MNL). ● Relative attribute importance (RAI) was calculated to measur
Slide 8: Results: Sample Characteristics
Results: Sample Characteristics ● 303 participants completed the web-based quantitative pilot survey. Variable N (%) Age, Mean (SD) [Range] 68.2 (6.4) [50-80] Female 115 (38.0) Race (White) 292 (96.4) Ethnicity (Hispanic) 10 (3.3) Education High school or less 64 (21.1) Associate degree, technical,
Slide 9: Results: Relative Importance of MCED Attributes
Results: Relative Importance of MCED Attributes Levels: 4, 25, 35, 56 false negatives out of 120 cancer cases Levels: 21, 42, 56, 83 true positives out of 120 cancer cases Levels: 70, 500, 1,000, 1,500 false positives in a population of 10,000 Levels: 1, 8, 20, 50 cancers tested for Levels: 0%, 5%,
Slide 10: Results: Preferences for Levels of MCED Attributes
Results: Preferences for Levels of MCED Attributes Results based on error-component multinomial logit model (EC-MNL) = p < 0.05 CONFIDENTIAL & PROPRIETARY 10
Slide 11: Results: Proportion of Participants Opting for MCED Screening
Results: Pr opor tion of Par ticipants Opting for MCED Scr eening 72% * MCED Screening No Screening 72% of participants indicated that they ** would pr efer a scr eening alter native r epr esenting GRAIL’s emer ging MCED test over no scr eening. *Reflects 99.3% specificity **Reflects 55% sensitivity
Slide 12: Conclusions
Conclusions ● Participants’ preferences were strongly driven by the desire for a screening test that minimized false negatives and maximized true positives, with these two attributes comprising 63.3% of the RAI. ○ This result suggests that patients are most concerned with accurately identifying exis
Slide 13: Thank you
Thank you CONFIDENTIAL & PROPRIETARY 13
Slide 14: Melissa M. Ross, PhD and Heather Gelhorn, PhD contact details
Melissa M. Ross, PhD Heather Gelhorn, PhD Research Scientist Senior Resear ch Leader Patient Centered Research Patient Center ed Resear ch Evidera Evider a Email: melissa.ross@evidera.com Email: heather .gelhor n@evider a.com Phone: 301-204-0468 Phone: 970-363-7333 Location: Bethesda, MD, USA Locati